Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
10399 studies found for:    NCI
Show Display Options
Rank Status Study
1 Completed GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Recurrent Adult Acute Myeloid Leukemia
Interventions: Biological: GTI-2040;   Drug: cytarabine;   Other: pharmacological study;   Other: laboratory biomarker analysis
2 Completed Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer
Condition: Breast Cancer
Interventions: Biological: recombinant fowlpox-CEA(6D)/TRICOM vaccine;   Biological: recombinant vaccinia-CEA(6D)-TRICOM vaccine;   Biological: sargramostim;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel;   Radiation: radiation therapy
3 Active, not recruiting Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies
Conditions: Adult Solid Neoplasm;   Stage IV Skin Melanoma
Interventions: Drug: Cediranib Maleate;   Drug: Selumetinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
4 Recruiting Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-Small Cell Lung Cancer
Conditions: Carcinoma of Unknown Primary Origin;   Extensive Stage Small Cell Lung Carcinoma;   Large Cell Lung Carcinoma;   Neuroendocrine Carcinoma;   Newly Diagnosed Carcinoma of Unknown Primary Origin;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Veliparib;   Other: Placebo;   Drug: Etoposide;   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
5 Recruiting Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Stage II Ovarian Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Drug: Veliparib;   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis
6 Active, not recruiting
Has Results
Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Conditions: Recurrent Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Biological: bevacizumab;   Drug: sorafenib tosylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
7 Completed Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer
Conditions: Recurrent Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: carboplatin;   Drug: bortezomib
8 Recruiting Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Conditions: Recurrent Thyroid Gland Carcinoma;   Stage I Thyroid Gland Follicular Carcinoma;   Stage I Thyroid Gland Papillary Carcinoma;   Stage II Thyroid Gland Follicular Carcinoma;   Stage II Thyroid Gland Papillary Carcinoma;   Stage III Thyroid Gland Follicular Carcinoma;   Stage III Thyroid Gland Papillary Carcinoma;   Stage IVA Thyroid Gland Follicular Carcinoma;   Stage IVA Thyroid Gland Papillary Carcinoma;   Stage IVB Thyroid Gland Follicular Carcinoma;   Stage IVB Thyroid Gland Papillary Carcinoma;   Stage IVC Thyroid Gland Follicular Carcinoma;   Stage IVC Thyroid Gland Papillary Carcinoma
Interventions: Drug: Cediranib Maleate;   Drug: Lenalidomide;   Other: Laboratory Biomarker Analysis
9 Completed Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
Conditions: Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Drug: imatinib mesylate;   Other: laboratory biomarker analysis
10 Recruiting Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Paclitaxel;   Drug: Docetaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
11 Active, not recruiting Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
Conditions: Recurrent Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: Sorafenib Tosylate;   Drug: Gemcitabine Hydrochloride;   Drug: Capecitabine
12 Completed Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
Condition: Extensive Stage Small Cell Lung Cancer
Interventions: Biological: oblimersen sodium;   Drug: carboplatin;   Drug: etoposide;   Other: pharmacological study;   Other: laboratory biomarker analysis
13 Completed Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: recombinant interferon alfa;   Biological: recombinant interleukin-12
14 Withdrawn Celecoxib in Preventing Skin Cancer
Condition: Non-melanomatous Skin Cancer
Interventions: Drug: celecoxib;   Procedure: anti-cytokine therapy;   Procedure: antiangiogenesis therapy;   Procedure: biological  therapy;   Procedure: cancer prevention intervention;   Procedure: chemoprevention of cancer;   Procedure: growth factor antagonist therapy
15 Terminated Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Stage II Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy;   Drug: paclitaxel;   Biological: bevacizumab;   Drug: carboplatin;   Other: laboratory biomarker analysis
16 Completed Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
Conditions: Cervical Cancer;   Fallopian Tube Cancer;   Head and Neck Cancer;   Lung Cancer;   Malignant Mesothelioma;   Ovarian Cancer;   Pancreatic Cancer;   Primary Peritoneal Cavity Cancer
Intervention: Biological: SS1(dsFv)-PE38 immunotoxin
17 Active, not recruiting Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer
Conditions: Adult Solid Neoplasm;   BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Hereditary Breast and Ovarian Cancer Syndrome
Interventions: Drug: Veliparib;   Drug: Carboplatin;   Drug: Paclitaxel;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
18 Active, not recruiting
Has Results
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Conditions: Mucosal Melanoma;   Recurrent Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Drug: sorafenib tosylate;   Other: placebo;   Other: pharmacological study;   Other: laboratory biomarker analysis
19 Completed
Has Results
Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIA Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma;   Stage IV Melanoma
Intervention: Drug: saracatinib
20 Active, not recruiting Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions: Drug: sorafenib tosylate;   Drug: temsirolimus;   Procedure: conventional surgery

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years